Instrument Inactif

Communiqués Kazia Therapeutics Ltd Australian S.E.

Actions

NRT

AU0000NRTDA2

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER	27/06	PR
Kazia Therapeutics : Appointment of Director Form 6 K	24/06	PU
Kazia Therapeutics : Securities Purchase Agreement - Form 6-K	17/05	PU
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS	01/05	PR
Kazia Therapeutics : Purchase Agreement - Form 6-K	19/04	PU
Kazia Therapeutics : Corporate Presentation	12/04	PU
Kazia Therapeutics : Half Yearly Report - 31 December 2023 - Form 6-K	27/03	PU
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases	21/03	PR
Kazia Therapeutics : EVT801 Progress Update Presentation	19/03	PU
Stocks Making Waves: Insights into Key Developments and Potential VTAK, TBIO, OCEA, ONMD, KZIA	27/02	AQ
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	21/02	AQ
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS	18/01	PR
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)	22/12	AQ
Kazia Therapeutics Announces $2 Million Registered Direct Offering	04/12	AQ
KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY	29/11	PR
KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING	21/11	PR
KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING	15/11	PR
KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA	10/11	PR
KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA	01/11	PR
KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY	23/10/23	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Kazia Therapeutics Ltd Australian S.E.

Actions

NRT

AU0000NRTDA2

Communiqués

Filtres